B-cell chronic lymphocytic leukemia (B-CLL) is characterized by accumulation of mature monoclonal CD5 þ B cells. The disease results mainly from a failure of cells to undergo apoptosis, a process largely influenced by the existence of constitutively activated components of B-cell receptor signaling and the deregulated expression of antiapoptotic molecules. Recent evidence pointing to a critical role of spleen tyrosine kinase (Syk) in ligand-independent BCR signaling prompted us to examine its role in primary B-CLL cell survival. We demonstrate that pharmacological inhibition of constitutive Syk activity and silencing by siRNA led to a dramatic decrease of cell viability in CLL samples (n ¼ 44), regardless of clinical and biological status and induced typical apoptotic cell death with mitochondrial failure followed by caspase 3-dependent cell death. We also provide functional and biochemical evidence that Syk regulated B-CLL cell survival through a novel pathway involving PKCd and a proteasomedependent regulation of the anti-apoptotic protein Mcl-1. Together, our observations are consistent with a model wherein PKCd downstream of Syk stabilizes Mcl-1 through inhibitory phosphorylation of GSK3 by Akt. We conclude that Syk constitutes a key regulator of B-CLL cell survival, emphasizing the clinical utility of Syk inhibition in hematopoietic malignancies.
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia in Western countries. It is characterized by the accumulation in primary and secondary lymphoid tissues and bone marrow of slowly dividing mature monoclonal CD5 þ B cells, expressing low levels of surface immunoglobulin (sIg). Clinically, CLL is heterogeneous with a stable form characterized by cells harboring IgM with mutated immunoglobulin variable heavy-chain (IgV H ) region genes and an aggressive form with cells expressing unmutated IgV H region genes and frequently associated with the expression of the protein tyrosine kinase zeta-associated protein at 70 kDa (ZAP-70) (Caligaris-Cappio and Hamblin, 1999; Kipps, 2003) . The disease results mainly from a failure of cells to undergo cell death rather than by excessive cellular proliferation. In addition to genetic or epigenetic modifications changing their intrinsic survival capacities, interactions of malignant B cells with their environment may enhance their resistance to apoptosis (Kipps, 2003) . Studies showing that antigenic stimulation through the B-cell receptor (BCR) may promote the selection and expansion of the neoplastic B-cell clone, supports the notion that BCR signals have a central role in the physiopathology of the disease (Stevenson and Caligaris-Cappio, 2004) .
BCR engagement regulates signaling pathways involved in B-cell development, proliferation, survival and differentiation (Niiro and Clark, 2002; Monroe, 2006) . In normal B-lymphocytes, BCR stimulation triggers the recruitment and activation of members of the Tec, Src and spleen tyrosine kinase (Syk) families of tyrosine kinases, followed by the activation of effector enzymes, including protein kinase C (PKC) isoforms, phosphatidyl 3-kinase (PI3K) and phospholipase Cg2 (PLCg2). These signaling complexes then regulate key downstream pathways, including the Ras-MAPK and Akt pathways, whose activities determine gene transcription and B-cell fate (Niiro and Clark, 2002) . In B-CLL cells, several studies have indicated the existence of constitutively activated components of the BCR-signaling pathway that participates to cell death resistance, such as Lyn (Contri et al., 2005) , PI3K and PKCd (Barragan et al., 2002; Ringshausen et al., 2002; Plate, 2004; Ticchioni et al., 2007) and Akt (Plate, 2004; Longo et al., 2008) . These constitutively activated-signaling pathways were proposed to participate to cell survival through regulation of anti-apoptotic molecules including Bcl-2 family members, XIAP and Mcl-1 (Cuni et al., 2004; Longo et al., 2008) . Thus, several pieces of evidence support the existence of cell-intrinsic signaling pathways promoting CLL cell survival with or without BCR engagement.
The SYK family of protein tyrosine kinase is composed of Syk and ZAP-70, two kinases initially identified in leukocyte signaling and in immunologic and allergic disorders (Latour and Veillette, 2001; Niiro and Clark, 2002; Wong et al., 2004) . However, studies now indicate that abnormal expression of Syk and ZAP-70 may also contribute to hematologic malignancies (Goodman et al., 2001; Crespo et al., 2006; Wossning et al., 2006; Feldman et al., 2008) . Other studies indicate that constitutively activated Syk may be a central determinant of B-CLL (Gobessi et al., 2009 ) and B-cell lymphoma survival (Leseux et al., 2006; Chen et al., 2008; Refaeli et al., 2008) . Altogether those studies suggest that Syk is a major component of neoplastic B-cell survival.
In this study, we examined the mechanisms by which Syk regulates ligand-independent survival of patient B-CLL cells. We demonstrate that pharmacological inhibition of Syk activity and depletion of its expression by siRNA-induced caspase 3-dependent apoptosis in CLL cells, regardless of biological and clinical status. We also provide evidence that Syk-regulated B-CLL cell survival through a novel pathway involving PKCd and a proteasome-dependent regulation of the antiapoptotic protein Mcl-1. Our study shows that Syk constitutes a key regulator of B-CLL cell viability.
Results

Constitutive phosphorylation of Syk in B-CLL cells
The kinase activity of Syk is regulated through the autophosphorylation of two tyrosine residues (Tyr525/ Tyr526) within its catalytic domain. To investigate the contribution of Syk activity in B-CLL cell survival, we first evaluated the level of Syk phosphorylation in resting primary leukemic cells. Immunoblot analysis showed a basal level of Syk phosphorylation on autophosphorylated Tyr525/Tyr526 regardless of ZAP-70 expression (Figure 1a ). This event was inhibited by the incubation of leukemic cells with the specific Syk inhibitor BAY61-3606, a compound acting as an ATP competitor blocking the catalytic activity of Syk (Yamamoto et al., 2003) . In contrast, the phosphorylation of Syk on the non-autophosphorylated tyrosine residue Tyr352, and of Lyn on Tyr416, was unaffected by the Syk inhibitor (Figure 1a ). Using the technique of phospho-flow cytometry, we further found that BAY61-3606 inhibited basal phosphorylation of Syk Tyr525/Tyr526, and the increased Syk phosphorylation induced on these residues following BCR stimulation (Figure 1b) . In contrast, BAY61-3606 had no effect on Syk Tyr352 phosphorylation detected on either resting or BCR-stimulated cells (Figure 1b) . These data indicate that treatment of CLL B cells with BAY61-3606 results in the specific inhibition of Syk activity.
Pharmacologic inhibition of Syk induces cell death in B-CLL cells
We next addressed the effect of Syk inhibition on CLL cell viability using flow cytometry combined to Annexin-V/7-AAD staining. In all patient cells tested (n ¼ 7), the Syk inhibitor-induced cell death at concentrations ranging from 0.5 to 10 mM, with a maximal cytotoxicity obtained for a concentration of 5 mM on six samples out of seven (Figure 2a) . A time course of cell death induction with 5 mM of BAY61-3606 showed a maximal cytotoxicity reached between 6 and 24 h (Figure 2b) . The treatment for 24 h with 5 mM of BAY61-3606 or vehicle alone was therefore chosen for testing the effect of Syk inhibition on cell survival from the 44 patient samples of this study (Figure 2c ). Under these conditions, the treatment with BAY61-3606 significantly reduced CLL cells survival (Po0.001, n ¼ 44). In contrast, Figure 2d shows that incubation for 24 h with 5 mM of BAY61-3606 was minimally toxic to normal peripheral B-lymphocytes (5 to 35% loss of cell viability), whereas it caused a dramatic loss of CLL cell viability (60 to 90% loss of cell viability). Next, we wished to determine whether differences in cytotoxicity following Syk inhibition could be observed in some CLL subsets. The sensitivity to BAY61-3606 treatment was examined on cells from patients whose clinical and biological features are defined in Supplementary Table S1 . This analysis showed that Syk inhibition potently reduced B-CLL cell survival, independently of IgV H gene mutation, ZAP-70 and CD38 expression (Supplementary Figure  S1) . The presence of chromosomal alterations disabling the p53 DNA damage cell checkpoint pathway has a major impact on disease progression and response to therapy (Kipps, 2003) . We thus examined the interaction between Syk and p53 pathways in CLL B cells. Syk inhibition triggered cell death in B-CLL cells refractory to the drug fludarabine and independently of p53 activation (Supplementary Figure S2) . Together, our data indicate that Syk regulates cell survival in CLL, regardless of clinical and biological status.
Inhibition of Syk activity induces apoptosis of B-CLL cells
We next assessed the pro-apoptotic effect of BAY61-3606 in B-CLL cells. First, electron microscopy analysis showed that cells treated with BAY61-3606 exhibited typical apoptotic morphology with highly condensed chromatin in treated cells as compared with control cells (Figure 3a) . Apoptosis was further evidenced by flow cytometric analysis of CLL cell viability. QVD-OPH, a pan-caspase inhibitor, completely reversed the decrease of cell viability induced by BAY61-3606 in cells from all patients examined (n ¼ 7) (Figure 3b) . A significant decrease of cell viability was observed after 48 h and 72 h of BAY61-3606 treatment in the presence of QVD-OPH, suggesting that a caspase-independent cell death process may also take place after long-term inhibition of Syk (Supplementary Figure S3) . To confirm apoptosis induction in CLL cells exposed to BAY61-3606, we examined caspase-3 activation by immunobloting. Upon BAY61-3606 treatment, processing of the zymogen form of caspase-3 to its active 19-kDa subunit was observed after 16 h, together with a marked cleavage of PARP, a known caspase-3 substrate (Figure 3c ). QVD-OPH abolished BAY61-3606-induced caspase-3 and PARP processing (Figure 3c ). The activation of caspase-3 following Syk inhibition was confirmed by flow cytometry using an antibody against active caspase-3. 
Syk silencing induces apoptosis in B-CLL cells
To sustain our data obtained with pharmacological inhibition of Syk activity, we next asked whether B-CLL cell survival is affected by specific depletion of Syk. For this purpose, we used siRNAs to knockdown Syk in The prosurvival activity of Syk is associated with PKCd activity We next investigated the nature of the biochemical pathways controlled by Syk in the regulation of B-CLL cell survival. We observed that treatment with the phorbol diester PMA, an activator of classical and novel PKCs, rescued the cytotoxic effect of BAY61-3606 on leukemic cells (Supplementary Figure S4a) and a reduced activity of the serine/threonine kinase PKCd has been implicated in CLL cell death (Barragan et al., 2002; Ringshausen et al., 2002) . As shown in Figure 5a , Syk inhibition decreased the phosphorylation of PKCd on Thr505 in all the tested samples (n ¼ 8/8). In contrast, BAY61-3606 had no significant effect on basal ERK1/2 and PKCa/b phosphorylation. Furthermore, downregulation of Syk expression by siRNA almost completely abolished the phosphorylation of PKCd on Thr505 in unstimulated CLL cells as compared with control cells (Figure 5b ). In addition, we found that siRNA-mediated downregulation of PKCd expression in B-CLL cells markedly reduced leukemic cell viability (Figures 5c and  d) . These results indicate that PKCd activity is a crucial event downstream of Syk in promoting B-CLL cell survival. Figure 3 Pharmacological inhibition of Syk results in apoptotic cell death. (a) CLL cells from patient no. 38 were incubated for 16 h with 5 mM of BAY61-3606. CLL morphology was analysed by electron microscopy. (b) CLL cells from seven patients were incubated for 1 h with 20 mM of the pan-caspase inhibitor QVD-OPH before treatment for 24 h with 5 mM of BAY61-3606. Apoptosis was assessed using Annexin-V/7-AAD staining. Values represent the mean ± s.d. of three independent measurements. (c) CLL cells from two patients were treated as described in (b). Cell lysates were separated by SDS-PAGE, transferred to nitrocellulose membrane, and immunoblotted with PARP and caspase-3 antibodies. (d) CLL cells were treated as described in (b). Upper panels: caspase-3 activity was assessed using a specific active caspase-3-FITC-labeled antibody as described in Materials and methods. Lower panels: measurement of mitochondrial potential (DCm) was assessed using MitoTracker Red 580 staining and analysed by flow cytometry. One experiment representative of three patient cell samples is shown.
QVD-OPH
consequence of caspase activity during apoptosis (Herrant et al., 2004) . Because Syk inhibition triggered caspase-3 activation in leukemic cells, we therefore evaluated the impact of caspase inhibition on Mcl-1 expression. For this purpose, cells were incubated or not with QVD-OPH before being subjected to BAY61-3606 treatment for 2 h and immunoblot analysis. In the absence of QVD-OPH, inhibition of Syk led to Mcl-1 downregulation, paralleled by caspase-3 processing. However, in the presence of QVD-OPH, whereas the levels of active caspase-3 were completely abolished, BAY61-3606 treatment still induced the downregulation of Mcl-1 (Figure 6d ). These results indicate that Mcl-1 downregulation is not a consequence of caspase activation, but rather represents a primary event downstream Syk and PKCd inhibition for regulating B-CLL cell apoptosis.
Inhibition of Syk leads to a proteasome-dependent degradation of Mcl-1 in B-CLL A recent study has shown that phosphorylation by GSK-3 targets Mcl-1 for proteasome-dependent degradation (Maurer et al., 2006) . Mcl-1 degradation could be regulated by the proteasome (Maurer et al., 2006) . To assess whether such a mechanism could take place downstream Syk and PKCd inhibition, B-CLL cells were incubated for 1 h with QVD-OPH or with the ubiquitin-proteasome inhibitor MG132 before treatment with BAY61-3606 and immunoblot analysis. Whereas treatment with QVD-OPH had no effect, blocking the proteasome with MG132 prevented the downregulation of Mcl-1 induced following Syk inhibition ( Figure 7a ). As a control, XIAP expression was not affected by BAY61-3606. We next examined whether Mcl-1 or a degradation-resistant mutant, Mcl-1 S159A (Maurer et al., 2006) could rescue cell death induced by the Syk inhibitor. To this end, B-CLL cells were nucleofected with V5-tagged Mcl-1 or Mcl-1 S159A (Figure 7b ), treated with BAY61-3606 and cell viability examined using Annexin-V/7-AAD staining. As shown in Figure 7c , ectopic expression of either Mcl-1 or Mcl-1 S159A in CLL cells from three patients rescued the cytotoxicity induced by BAY61-3606 in CLL cells from three patients. However, the protection induced by Mcl-1 S159A was significantly stronger than that observed with wild-type Mcl-1 (Po0.05). In addition, immunoblot analyses showed that Mcl-1 S159A was more resistant to degradation induced by BAY61-3606, compared with wild-type Mcl-1 (Figure 7d ). Finally, we found that siRNAmediated suppression of PKCd decreased both Akt and GSK-3 phosphorylation (Figure 7e ). Together with our observation that inhibition of Syk also reduced Akt phosphorylation in patient cell samples displaying constitutive Akt activity (Supplementary Figure S5) , these results strongly support the notion that Syk acts upstream of PKCd in B-CLL to regulate Mcl-1 expression through a proteasome-dependent process. 
Discussion
Human CLL B cells display high activities of protein kinases and effector enzymes involved in BCR signaling and leukemic cell survival (Ringshausen et al., 2002; Plate, 2004; Contri et al., 2005; Ticchioni et al., 2007; Longo et al., 2008) . The molecular origin of activatedsignaling pathways found in mature B-cell neoplasms, including B-CLL, is still unclear. Constitutive phosphorylation of Syk has been reported in B-CLL cells (Semichon et al., 1997; Lanham et al., 2003; Deglesne et al., 2006) , and in B-cell lymphoma (Leseux et al., 2006; Chen et al., 2008) . A ligand-independent BCR signaling, also called tonic signaling (Monroe, 2006) , has been recently involved in the constitutive activation of Syk found in B-cell lymphoma (Chen et al., 2008) . CLL cells express low levels of sIg, a property shared by murine anergic B cells (Chiorazzi and Ferrarini, 2003; Stevenson and CaligarisCappio, 2004) , which exhibit high levels of tyrosine phosphorylation along with activated-signaling pathways (Gauld et al., 2005) . Accordingly, constitutive activation of ERK1/2 in the absence of Akt activation has been linked to anergy in some CLL subsets (Muzio et al., 2008) . However, our observations suggest that the anergic status of CLL cells has no significant implication in Syk-dependent CLL cell survival. Indeed, inhibition of Syk had no effect on basal ERK1/2 phosphorylation, and all cases in our cohort of B-CLL were sensitive to Syk inhibition. Recent studies have associated the presence of ZAP-70 in unmutated CLL cases with increased signaling following BCR ligation, including enhanced Syk phosphorylation (Chen et al., 2002 (Chen et al., , 2005 . However, we found that neither sIg mutation status nor ZAP-70 expression had a statistically significant impact on apoptosis induced by Syk inhibition. Thus, it is possible that the activity of Syk found in resting CLL cell stems from the stereotyped BCR repertoire identified in CLL cells (Messmer et al., 2004) , which may affect BCR tonic signaling. Alternatively, constitutive Syk activity may arise from deregulated protein tyrosine phosphatases, such as protein tyrosine phosphatase receptor type O (PTPROT), a phosphatase involved in tonic BCR signaling (Chen et al., 2006) and the promoter of which was found epigenetically inactivated in CLL (Motiwala et al., 2007) . Thus, the constitutive activity of Syk found in CLL cells may have different molecular origins, and further investigations aimed at their identifications are warranted. Using BAY61-3606, a specific ATP-competitive Syk inhibitor used in inflammatory and allergic diseases (Yamamoto et al., 2003) , we showed that targeting Syk activity in B-CLL induced a typical mitochondrial apoptotic cell death. Interestingly, a recent report showed that another Syk pharmacologic inhibitor (R406) also induced apoptosis in CLL cells (Gobessi et al., 2009) . To consolidate our pharmacological approach, we knocked down Syk in CLL cells from 21 patients. Again, the reduction of Syk expression by siRNA decreased cell viability and induced apoptosis. We also showed that Syk inhibition triggered apoptosis independently of p53 activation, and in B-CLL cells resistant to the chemotherapeutic drug fludarabine. This indicates that Syk may regulate cell survival in aggressive CLL cases wherein chromosomal alterations have disabled the p53 DNA damage checkpoint pathway. Whether Syk survival pathway cooperates with other treatments in CLL cells is unknown.
How Syk regulates CLL cell survival? In normal B-lymphocytes, Syk triggers multiple signaling pathways downstream BCR and functional interactions between Syk and Src family kinases such as Lyn are well described (Niiro and Clark, 2002; Monroe, 2006) . Inhibition of Lyn by dasatinib triggers cell death in CLL cells (Veldurthy et al., 2008) . BAY61-3606 had no effect on the phosphorylation of Syk Tyr352 (a target residue for Src kinases), Lyn and Erk1/2 (a primary target of Src kinases in lymphoid cells including CLL (Veldurthy et al., 2008) ), indicating that Syk inhibitor did not proceed through non-specific Src kinase inhibition. Several other signaling molecules may participate to cell death resistance downstream of Syk, including PI3K, Akt and PKC (Ringshausen et al., 2002; Plate, 2004; Holler et al., 2009) . The pro-survival role of Akt in CLL has been recently demonstrated (Longo et al., 2008) , and another pharmacologic inhibitor of Syk inhibited the Akt activity (Gobessi et al., 2009) . In agreement with this study, we also observed that BAY61-3606 similarly affected Akt activity. However, a fraction of CLL cells from our cohort displayed no detectable phosphorylation of Akt, consistent with previous studies (Muzio et al., 2008) . Despite absence of activated Akt, B-CLL cells from those particular patients were totally sensitive to Syk inhibition, suggesting the existence of alternative or redundant pathways downstream of Syk in CLL survival. Consistent with this notion, while having no effect on PKCa/b activity, Syk inhibition and knock down decreased phosphorylation of PKCd, a protein kinase involved in B-CLL, but not in normal B-cell survival (Ringshausen et al., 2002) . This stands in apparent contradiction with other cell types, wherein PKCd is regarded as a pro-apoptotic molecule (Reyland, 2007) . However, further supporting the important role of PKCd in Syk-mediated CLL cell survival, siRNA-mediated PKCd silencing markedly reduced cell viability, as well as Akt phosphorylation. How Syk regulates PKCd activity in CLL B cells is currently unknown. It is well known that Syk phosphorylates and activates PLCg2 in B cells (Monroe, 2006) , generating lipid second messengers that activate PKCs, including PKCd (Steinberg, 2004) . However, neither BAY61-3606 nor Syk siRNA inhibited PLCg2 phosphorylation in CLL B cells (data not shown). Another potential mechanism could implicate a direct link between Syk and the p85 subunit of PI3K (Moon et al., 2005) , and PI3,4,5-P3-dependent activation of PKCd (Toker et al., 1994) . Further investigations are clearly required to determine the mechanisms by which Syk regulates PKCd activity in CLL.
The increased survival of B-CLL cells is believed to be a consequence of the altered balance between Bcl-2 family proteins. Indeed, high levels of Bcl-2, Mcl-1, BclxL, Bax and Bim have been found in the majority of CLL cells (Kitada et al., 1998; Kipps, 2003; Saxena et al., 2004) . Elevated levels of Mcl-1 in CLL have also been associated with increased survival, resistance to chemotherapy and poor prognosis Petlickovski et al., 2005; Longo et al., 2008; Pepper et al., 2008) . Although the expression of another cell survival regulator, XIAP, was not affected, Syk inhibition or depletion regulated Mcl-1 expression at the protein level. Consistent with our findings, the Syk inhibitor R406 was shown to decrease Mcl-1 expression in CLL cells (Gobessi et al., 2009) . However, we provide additional evidence that Mcl-1 downregulation was not a consequence of caspase activation and apoptosis, but rather resulted from an ubiquitin-proteasome-dependent mechanism, as shown by the reversal of BAY61-3606-induced Mcl-1 degradation by MG132. Furthermore, an ectopically expressed form of Mcl-1 mutated on the GSK-3 site (Mcl-1 S159A) (Maurer et al., 2006) was more resistant to proteolysis induced by BAY61-3606 treatment compared with Mcl-1, and more significantly rescued the cytotoxic effect of Syk inhibition. Although other mechanisms cannot be excluded, our observations suggest that Mcl-1 degradation is a primary and critical event in cell death inducted by targeting Syk in CLL. Importantly, expression of PKCd was shown to be required for Akt and GSK-3 phosphorylation, and Mcl-1 stabilization. However, Syk inhibition also leads to Mcl-1 degradation in CLL cases in which no significant phosphorylation of Akt was detected, indicating the existence of redundant pathways. In addition to Akt, several kinases were shown to phosphorylate the inhibitory N-terminal site of GSK-3, including PKCs (Fang et al., 2002) . Thus, we would like to propose that, in the absence of active Akt in CLL, Syk might regulate GSK-3 through direct phosphorylation by PKCd.
The phosphorylation of Mcl-1 by GSK-3 was recently shown to target Mcl-1 for degradation by the proteasome (Maurer et al., 2006) . Together, these observations are consistent with a model wherein PKCd downstream of Syk stabilizes Mcl-1 through inhibitory phosphorylation of GSK-3. In the majority of CLL samples displaying active Akt, our model is further supported by our observations that inhibition of Syk also reduced Akt phosphorylation (Supplementary Figure S5 , and data not shown), and those from Gobessi et al. (Gobessi et al., 2009) . How Syk/PKCd regulates the Akt/GSK-3 pathway to the ubiquitin proteasome system is currently under investigation. In addition, identifying which E3 ubiquitin ligase(s) targets Mcl-1 for degradation downstream Syk/PKCd signaling would be of special interest to our understanding of the pathogenesis of CLL.
In conclusion, our data show that Syk has a key role in B-CLL cell survival through PKCd and proteasomedependent regulation of Mcl-1 expression, indicating that Syk is an attractive target in CLL. Whether similar mechanisms also regulate cell survival in other B-cell neoplasms needs additional investigations.
Materials and methods
Patients, cell isolation and culture Leukemic cells were obtained at the Centre Hospitalier Universitaire of Nice from peripheral blood samples of 44 CLL patients after informed consent. The diagnosis of B-CLL was based on clinical and immunophenotypic criteria. All patients included in this study were either untreated or had not received chemotherapy or steroids for at least 6 months before the investigation. Peripheral mononuclear cells were isolated from peripheral blood by Ficoll-Hypaque density gradient centrifugation. Leukemic B cells were isolated by magnetic selection as previously described (Ticchioni et al., 2007) . Cells were cultured at a concentration of 1x10 6 per ml in RPMI-1640 medium (Gibco BRL, Paisley, UK) containing 10% FCS (Hyclone, Logan, UT, USA), 1 mM L-glutamine and 1 mM pyruvate. Note that the differences in viability of frozen versus freshly isolated leukemic cells did not modify the relative effect of the different treatments on in vitro cell survival.
Reagents, antibodies, plasmids and siRNA BAY 61-3606 and phorbol myristate acetate (PMA) were purchased from Sigma Aldrich (St Louis, MI, USA). QVD-OPH was from MP-Biomedicals (Aurora, OH, USA). Antibodies against caspase 3, PARP, XIAP, Akt and phosphorylated forms of Syk, PKCd, PKCa/b, Akt, GSK-3 and HRPconjugated secondary antibodies were from Cell Signaling Technology (Beverly, MA, USA). Antibodies against Syk, PKCd, PKCa/b, ERK2, Hsp60, Mcl-1 and siRNA against PKCd were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-CD5, CD19 and CD38 antibodies were from Becton Dickinson (San Jose, CA, USA). Anti-V5 antibody and siRNAs against Syk were from Invitrogen (Paisley, UK). V5-tagged Mcl-1 and Mcl-1 S159A constructs were generated as described (Maurer et al., 2006) . Analysis of apoptosis, caspase 3 activity and mitochondrial membrane potential by flow cytometry Apoptosis was evaluated by flow cytometry following double staining with annexin-V-PE and 7-AAD as previously described (Ticchioni et al., 2007) .
To assess caspase-3 activity, cells were fixed and permeabilized with Cytofix/Cytoperm as above, then incubated for 30 min with anti-active caspase-3-FITC antibody. Analysis was performed by flow cytometry.
The mitochondrial membrane potential was analysed by measuring the accumulation of the mitochondrial probe MitoTracker Red580 (Molecular probes, Eugene, OR, USA). One million of cells were incubated at 37 1C for 30 min in HBSS (Gibco BRL) with 100 nM MitoTracker Red580, washed and analysed by flow cytometry.
Cell transfection
Transient transfections into human B-CLL cells were performed using the AMAXA nucleofection system (AMAXA Gmbh, Koln, Germany) as described previously (Ticchioni et al., 2007) . Briefly, cells were resuspended in 100 ml of Buffer V, mixed with 5 mg of plasmid DNA or 2 mM of siRNA duplex, electroporated using program U-015 and incubated at 37 1C, 5% CO 2 before treatment.
Immunoblot and Immunoprecipitation analysis
Cell lysis, immunoprecipitation and immunoblot analyses were performed as previously described (Ticchioni et al., 2007) .
Electron microscopy Cells were fixed in situ with 1.6% glutaraldehyde in 0.1 M phosphate buffer pH 7.5 at room temperature, washed with same buffer and then postfixed with 1% osmium tetroxyde and 1% potassium ferricyanid. Finally, cells were rinsed with distilled water, dehydrated with ethanol and embedded in Epon. Thin sections were contrasted with uranyl acetate and lead nitrate and observed with a Philips transmission electron microscope.
Statistical analysis
The nonparametric Wilcoxon's signed rank test for paired measures was used to evaluate variations in leukemic cell viability following pharmacological or siRNA treatment. A generalized linear model with a binomial probability distribution was used to compare the effect of clinical status on B-CLL cells viability after BAY61-3606 treatment. The MannWhitney U-test was used to evaluate differences in cell viability between B-CLL and healthy volunteers after BAY61-3606 treatment. Statistical analyses were performed using the SAS software.
